Navigation Links
UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
Date:4/3/2012

eir nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations,  changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees.  UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

Abou
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... SAN DIEGO , Sept. 16, 2014 /PRNewswire/ ... acquired enzastaurin, a late-stage oncology drug, from Eli ... rights to develop, manufacture and commercialize enzastaurin globally, ... rights, data, and information. Lilly ... in Phase 2 and Phase 3 clinical trials ...
(Date:9/16/2014)...  Decision Resources Group finds that the rheumatoid arthritis (RA) disease-modifying ... over $18.2 billion in 2023 in the United States ... , Italy , Spain , ... . TNF-alpha inhibitors will remain the leading drug class in ... will be constrained and patient shares will decline due to the ...
(Date:9/16/2014)... , Sept. 16, 2014   HemCon Medical ... of TriStar Wellness Solutions(R), Inc. (OTCQB: ... advanced medical products, announced today that the revenue ... by 39 percent, and microdispersed oxidized cellulose raw ... 2014.  Overall, TWSI expects third quarter revenues to ...
Breaking Medicine Technology:Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3HemCon Medical Technologies, Inc. Projects Strong Third Quarter Revenues 2HemCon Medical Technologies, Inc. Projects Strong Third Quarter Revenues 3HemCon Medical Technologies, Inc. Projects Strong Third Quarter Revenues 4
... April 26 Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... treatment of cancer, today announced that it will host a conference call ... Wednesday, May 5, 2010 , at 8:30 AM ET . , ... To participate in the conference ...
... , April 26 Cornerstone Therapeutics Inc. (Nasdaq: ... developing and commercializing significant products primarily for the respiratory and ... call at 8:00 AM ET on Tuesday, ... the quarter ended March 31, 2010 .  Management will ...
Cached Medicine Technology:Micromet to Report First Quarter 2010 Financial Results on May 5 2Cornerstone Therapeutics to Host First Quarter 2010 Conference Call 2Cornerstone Therapeutics to Host First Quarter 2010 Conference Call 3
(Date:9/17/2014)... Tampa, FL (PRWEB) September 17, 2014 Tina ... ), is finishing up her chemotherapy but not her fight ... up for the Komen Florida Suncoast “Race for the Cure” ... “I registered for the Komen Race for the Cure because ... breast cancer,” Griffin said. , As part of her efforts, ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Four ... eighth annual Wailea Tennis Fantasy Camp on ... Maui’s prestigious Wailea Tennis Club, with three-time grand slam ... returning to Wailea, Maui for her fifth year. , ... match play with Davenport, recently inducted into the International ...
(Date:9/17/2014)... September 17, 2014 A raucous childhood ... come together to form author Nancy Chovancek’s laughter-filled new ... is a collection of short stories that prove the ... fun. With a positive message of empowerment and resilience, ... is a proven author with two books under her ...
(Date:9/17/2014)... This September 18-20, 22 participating developmentally-disabled athletes ... three stage outdoor sporting event in non-profit World T.E.A.M. ... , Hosted at The Center for Discovery ... five participating teams coached by able-bodied athletes. For each ... provide expert guidance as well as technical assistance. Like ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 Lee ... settlement industry, will be appearing on The Balancing Act® ... two September episodes. , The segment will premiere on ... on 'The Balancing Act® airing on Lifetime Television®' with ... of Asset Funding Corp. for over a decade and ...
Breaking Medicine News(10 mins):Health News:Tina Griffin’s Fight Against Cancer Didn’t Stop With her Chemotherapy—Her Next Step Is to Run in the Suncoast ‘Race for the Cure’ Oct. 11 2Health News:Four Seasons Resort Maui at Wailea Announces 8th Annual Wailea Tennis Fantasy Camp 2Health News:Four Seasons Resort Maui at Wailea Announces 8th Annual Wailea Tennis Fantasy Camp 3Health News:World T.E.A.M. Sports’ Adventure Team Challenge New York Includes Disabled Athletes 2Health News:World T.E.A.M. Sports’ Adventure Team Challenge New York Includes Disabled Athletes 3Health News:Lee Berman Will Appear On The Balancing Act® airing on Lifetime Television® 2
... Polyp Detection by Thirteen Percent, SAN DIEGO, ... in San Diego (DDW 2008), world-renowned gastroenterologist,Jerome D. ... which evaluated the efficacy of the Third Eye(TM) ... physicians to visualize,abnormalities in the colon., The ...
... near Mosul in 2003 , , WEDNESDAY, May 21 (HealthDay News) ... near Mosul, Iraq, in 2003 returned home with a debilitating ... , But doctors were only able to diagnose the condition, ... to reliably identify the problem, said the authors of a ...
... (Amex: QGP, QGP.WSA, QGP.WSB) ( http://www.QuantumMD.com ) ... plan. The Company,increased its employment base by 23% since ... ft. to 10,600 sq. ft., and has moved a,branch ... Doral (west,Miami), Florida., Susan Darby Guillama, Executive Vice ...
... MINNEAPOLIS, May 21 ACM today announced a ... development efforts on,providing next generation technology and services ... of healthcare today: commercial plans and,payers, and federal ... Development Gary Loeber has been,named EVP/General Manager for ...
... that patients with chronic obstructive pulmonary disease (COPD) who ... visits from exacerbations or complications benefit from simple low-intensity ... for COPD was previously shown to reduce hospitalizations for ... a more limited intervention model is effective, said Kathryn ...
... Calif., May 21 LUMEDX Corporation, a ... information systems,(CVIS), introduces software to manage data ... The Anticoagulation Module empowers clinicians,by making critical ... safety., For more information -- including ...
Cached Medicine News:Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 2Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 3Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 4Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 5Health News:Some Iraq War Vets Suffer Breathing Problems 2Health News:Some Iraq War Vets Suffer Breathing Problems 3Health News:The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009 2Health News:The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009 3Health News:ACM Taps Two Senior Leaders to Head Up New Strategic Initiatives 2Health News:Low-intensity case management cuts COPD-related hospital visits in half 2Health News:New Anticoagulation Management Software Helps Clinics Enhance Efficiency and Improve Patient Safety 2
... Distriman is a ... that is designed to ... used with Gilson DistriTip ... polypropylene syringes with level ...
... lightweight and balanced for smooth, one-handed control. ... comfort, reducing fatigue in even the longest ... physician to easily steer the catheter through ... one finger. Reflexion's auto-lock technology keeps the ...
... performance technologies - Quantum™ LEAP® balloon ... - unite in the Quantum™ Maverick® ... dilatation force balloon with exceptional deliverability. ... Maverick® shaft technology improves trackability and ...
... Libert Coronary Stent System ... of lesion access and ... a low crossing profile, ... catheter, the performance of ...
Medicine Products: